Tilray Brands, Inc. Q1FY27 Earnings Call - TILRAY BRANDS INC

Financial Performance:

• Q1 2027 net revenue reached a record $257.1 million, up 23% year-over-year (YoY), driven by BrewDog acquisition and international cannabis growth.
• Consolidated gross profit hit a record $77.5 million (up 35% YoY), with gross margins expanding 300 basis points to 30%.
• Adjusted EBITDA for the quarter was $9.2 million (down from $10.2 million YoY), impacted by $8.8 million in international cannabis price compression and $1.7 million in fuel surcharges.
• Net loss reported was $40 million; adjusted net loss was approximately $3 million, heavily influenced by $5 million in net cash interest expense.
• Cannabis segment gross margin improved 300 basis points to 39% despite price compression, aided by Portugal facility efficiency and product mix.
• Beverage segment revenue surged 82% YoY to $101.5 million, with gross margins expanding 300 basis points to 41%.
• Distribution revenue grew 14% to $84.3 million; wellness revenue remained stable at $15.3 million.
• Ended the quarter with $221 million in cash, restricted cash, and marketable securities; retired $24 million in debt principal during the quarter with $52 million outstanding.

Guidance and Future Outlook:

• Reaffirmed Fiscal 2027 adjusted EBITDA guidance of $68 million to $75 million despite short-term headwinds.
• Management anticipates a seasonally stronger second half of the fiscal year.
• Long-term goals include leveraging global scale to absorb $500 million to $1 billion in additional sales while maintaining cost structures.
• Expect BrewDog to remain profitable and contribute significantly to future growth through global expansion and new distribution points.
• Carlsberg partnership revenue contribution expected to begin immediately upon the January 1, 2027, transition of production and sales rights in the U.S.
• Anticipates U.S. cannabis reform and potential hemp bill extensions to unlock future upside, though the company will grow regardless of specific regulatory outcomes.

Business Segments and Product Lines:

• Cannabis: International cannabis revenue grew 21% YoY; EU GMP shipments surged with flower (+110%) and oil (+150%). Portugal facility reduced operating costs by 40% and is on track to produce 40+ metric tons of flower.
• Beverages: BrewDog became profitable in Q2 (fiscal year context) and Q1 results showed strong momentum; launched "Under New Ownership" and "Choose Craft" campaigns. U.S. craft beer business saw Sweetwater brand up 21% FYTD and Montauk Juicy IPA up 25%.
• Partnerships: Exclusive multi-year partnership with Carlsberg Group to produce and distribute Carlsberg, 1664, and Kronenbourg 1664 in the U.S. starting Jan 1, 2027.
• Wellness: Manitoba Harvest expanding into plant-based products and new wellness occasions; supply constraints on organic hemp seed temporarily affected e-commerce channels.
• Distribution: CC Pharma distribution network expanded to over 16,000 pharmacies in Europe, serving as a strategic connector for medical cannabis.
• Hospitality: Operates nearly 40 venues (pubs, bars, hotels) globally, including 9,000 new BrewDog distribution points and 8 new on-trade partnerships.

Market and Competitive Landscape:

• Cannabis: Positioned as the world's largest cannabis grower with 6 million sq. ft. capacity; leading position in Canada and Europe (Germany, UK, Portugal, Poland).
• Beverage: Number one craft beer supplier in the UK and fourth largest total beer supplier in UK grocery; fourth largest craft brewery in the U.S.
• Competition: Acknowledges pricing compression in international cannabis markets and distributor consolidation in the U.S. craft beer sector.
• Market Share: Holding >40% market share in Canadian THC beverages; leading medical cannabis growth in Germany and Portugal with high EU GMP standards.
• Macro Trends: Navigating fuel surcharges due to geopolitical instability and input cost inflation, while optimizing route-to-market strategies against distributor consolidation.

Risks and Challenges:

• Regulatory Uncertainty: Delays in U.S. cannabis rescheduling and pending hemp bill extensions create market sentiment volatility.
• Pricing Pressure: International cannabis markets face price compression, partially offset by volume growth and margin improvements.
• Cost Headwinds: Rising fuel surcharges and inflation impacting input costs, though mitigated by operational efficiencies.
• Integration Risks: Ongoing integration of BrewDog and U.S. craft beer portfolio rationalization (brewery closures, distributor consolidation).
• Supply Constraints: Temporary shortages of organic hemp seed affected wellness e-commerce; planned strain rotations in Canada caused Q1 supply constraints.

Management Commentary and Tone:

• Tone: Highly confident, emphasizing diversification, global scale, and the transition from a pure-play cannabis model to a multi-category global consumer goods platform.
• Narrative: Management consistently frames Tilray not as a single-market entity but as a diversified business with multiple growth engines (cannabis, beverage, wellness, distribution) that can withstand regulatory delays in any single region.
• Strategic Focus: Emphasis on "profitable growth," cost discipline, and converting infrastructure into cash flow and earnings power.
• Shareholder Value: Explicit focus on reducing interest burden, strengthening the balance sheet, and generating free cash flow to support dividends or buybacks in the future.

Analyst Questions and Answers:

• International Cannabis Dynamics: Management expressed confidence in long-term growth despite potential competitor combinations, citing strong infrastructure, low-cost production in Portugal, and the CC Pharma distribution network (16,000 pharmacies) as competitive moats.
• Beverage Gross Margins: Confirmed margin expansion is driven by facility consolidation (reducing from 8-10 breweries to 5-6), gaining scale efficiencies from the Carlsberg partnership, and shifting towards direct-to-retail sales (Walmart, Kroger) rather than relying solely on distributors.
• BrewDog Profitability: Explained the quick turnaround was achieved through right-sizing headcount, avoiding new lease obligations via administration, shutting down unprofitable spirits operations, and leveraging strong seasonal performance during the World Cup.
• Carlsberg Partnership Upside: Described as a profit-sharing venture where Tilray manufactures, markets, and distributes Carlsberg brands in the U.S. with potential for future mutual distribution in other global markets.
• M&A Strategy: While open to strategic acquisitions, current focus is on maximizing synergies between existing beverage and cannabis portfolios (e.g., cannabis beverages) and organic growth; Canada market size limits further cultivation M&A, but product expansion is key.
• Germany Reimbursement Changes: Clarified that the majority of business is out-of-pocket for flower; oil reimbursement changes for new patients have minimal impact on overall business volume.

Other Key Points:

• Tilray operates in over 25 countries with production and sales spanning three major time zones and multiple currencies.
• The company produces 95% of its own products globally, including a proprietary genetics bank.
• Management highlighted the potential for $1 billion+ in cannabis beverage revenue in the U.S. if regulations allow sales in bars and restaurants.
• Acknowledged that the stock market often mislabels Tilray as a pure-play cannabis operator despite its significant non-cannabis revenue streams.
• BrewDog's "Choose Craft" campaign saw Punk IPA sales at top six off-trade retailers increase 187% in the two weeks following the launch.